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Abstract
Objective: The aim of this study was to evaluate the effectiveness of oxy-
butynin in the treatment of nocturia in patients with overactive bladders 
(OAB) and to assess predictive factors for the responses to oxybutynin.
Patients and Methods: Patients with symptoms of OAB and nocturia for 
more than 3 months were enrolled. A 2.5 mg dose of oxybutynin was 
given twice daily for 1 week after a baseline study that included a self-
administered nocturia questionnaire, uroflowmetry, and frequency/volume 
chart. Outcome analysis included changes in nocturia episodes, uroflow-
metry, and post-void residual urine. Patients were stratified according to a 
nocturia index (Ni), nocturnal polyuria index (NPi), and nocturnal bladder 
capacity index (NBCi).
Results: A total of 59 patients were eligible for analysis. After 1 week 
of treatment with oxybutynin, the mean number of nocturia episodes 
had reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p < 0.01). There were no statisti-
cally significant differences in the mean reduction of nocturia episodes 
between the subgroup of patients with NPi ≤ 0.35 and those with NPi 
> 0.35 (−0.4 vs. −0.3, p = 0.34, ANCOVA). Reduction in number of nocturia 
episodes was more significant in patients with Ni ≤ 1.5 than in those with 
Ni > 1.5 (−0.9 vs. −0.2, p = 0.03, ANCOVA), and in patients with NBCi > 2 
than in those with NBCi ≤ 2 (−1.1 vs. −0.2, p = 0.01, ANCOVA).
Conclusion: Ni and NBCi are good predicting factors for the effects of 
antimuscarinic agents on nocturia in patients with OAB. [Tzu Chi Med J 
2008;20(4):304–308]
Article info
Article history:
Received: January 4, 2008
Revised: January 24, 2008
Accepted: April 4, 2008
Keywords:
Antimuscarinic
Nocturia
Overactive bladder
© 2008 Buddhist Compassion Relief Tzu Chi Foundation
1. Introduction
Nocturia usually coexists with an overactive bladder 
(OAB). In a survey in the United States [1], 66.8% of 
OAB cases reported more than one void per night 
and 42.2% reported more than two voids per night. 
Nocturia is usually underreported by both patients 
and clinicians since most people deem nocturia as a 
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part of the aging process. However, nocturia impairs 
patients’ quality of life and has detrimental effects on 
health [1]. Incremental increase in the number of voids 
per night has negative effects on sleep and quality of 
life, and is a bothersome symptom.
Nocturia can be caused by increased nighttime 
urine output, decreased nocturnal functional bladder 
capacity, or a mixed etiology of the two. Despite the 
fact that many physicians use anticholinergic agents 
to treat nocturia by increasing bladder capacity and 
thus decreasing nocturia episodes, there have been 
few studies on the treatment of nocturia using anti-
cholinergics. The results remain controversial. Chapple 
et al [2] evaluated the effectiveness of darifenacin, a 
selective M3 receptor antagonist, in OAB patients in 
a double-blind, placebo-controlled study. No signifi-
cant reduction in nocturnal awakenings was observed 
compared with patients in the placebo control group 
after 12 weeks of medication. Brubaker and Fitzgerald 
[3] conducted a randomized, double-blind study to 
ev aluate the effectiveness of solifenacin and con-
cluded that solifenacin improved symptoms only in 
OAB patients without nocturnal polyuria. Patients 
with reduced nocturnal bladder capacity were not 
specified in their study.
Because antimuscarinic agents can suppress volun-
tary and involuntary bladder contractions and thereby 
increase functional bladder capacity, we hypothesized 
that patients with reduced nocturnal bladder capac-
ity will benefit from them. Hence, this study was con-
ducted to evaluate the effectiveness of oxybutynin in 
treating OAB patients with nocturia, and to assess the 
predictors for response.
2. Materials and methods
From July 2006 through January 2007, 95 adults 
presenting with the symptoms of frequency > 8 times/
day and urgency with or without incontinence for at 
least 3 months were enrolled. Baselines for the study 
included results of medical history, physical exami-
nation, urine analysis, urine culture, uroflowmetry, 
and a 2-day frequency/volume chart (FVC). Patients 
with nocturnal void (urination preceded by sleep) 
more than once per night were included for analysis. 
Patients with previous history of major abdominal 
surgery, neurological disease, and concurrent medi-
cation of alpha-blockers, diuretics, and anticholiner-
gics were excluded. Male patients aged > 50 years were 
also excluded since prostatism in aging men may 
confound the results of oxybutynin response.
After baseline evaluations, patients were treated 
with 2.5 mg of oxybutynin two times per day for 1 
week. Patients completed uroflowmetry and nocturia 
questionnaire (for example, “How many times do you 
typically get up at night to urinate?” 0 = no nocturia; 
1 = one time; 2 = two times; 3 = three times; 4 = four 
times; 5 = five times or more) at baseline and at week 
1 for evaluation of responses to treatment. Patients 
were asked to void in private and post-void residual 
urine was measured using transabdominal ultrasound. 
Changes in nocturia episodes were determined from 
the differences at baseline and at week 1.
Definitions used in this study conformed to the 
standards recommended by the International Conti-
nence Society (ICS), except where special cases were 
noted [4]. Nocturnal urine volume was calculated as 
the total volume of urine voided during the night and 
the first void in the morning after waking. Total daily 
urine volume was calculated as the total urine voided 
in a 24-hour period. Maximum voided volume (MVV) 
was the largest volume of urine voided during a single 
micturition determined from the voiding diary. From 
the FVC, nocturnal polyuria index (NPi), nocturia index 
(Ni) and nocturnal bladder capacity index (NBCi) were 
generated [5]. NPi was calculated as “nocturnal urine 
volume/total daily urine volume”, while Ni was calcu-
lated as “nocturnal urine volume/the largest single 
volume voided in a 24-hr FVC”. NBCi was defined as 
“actual number of nightly voids – predicted number of 
nightly voids”, while the predicted number of nightly 
voids was calculated as “Ni – 1”.
Patients were further divided into subgroups accord-
ing to NPi (cut-off value = 0.35), Ni (cut-off value = 1.5), 
and NBCi (cut-off value = 2). Responses to oxybutynin 
were compared among the subgroups.
Data were expressed as mean ± standard deviation 
or percentages and were analyzed using commercially 
available statistical software (Medcalc® version 9.3; 
MedCalc Software, Mariakerke, Belgium). Paired t test 
was used to compare changes in parameters between 
the end point and baseline. Differences in therapeu-
tic responses between groups were analyzed using 
analysis of covariance (ANCOVA) using baseline noc-
turia episodes as covariates. A p value less than 0.05 
was considered significant.
3. Results
A total of 59 (62.1%) patients were eligible for analysis 
in this study after excluding those lost to follow-up 
(n = 5), intolerance of adverse effects (n = 1), incom-
plete records of voiding diaries and symptom scores 
(n = 20), total daily urine volume > 3000 mL (n = 4), and 
absence of nocturia (n = 6). Demographic data are 
listed in Table 1. After 1 week of treatment with oxybu-
tynin, the mean number of nocturia episodes reduced 
from 2.7 ± 1.3 to 2.3 ± 1.1 (p < 0.01). There were no 
significant changes in peak flow rate, voided volume, 
and post-void residual urine at the end point (all 
p > 0.05). There were no significant differences in re-
duction in the number of nocturia episodes between 
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male and female patients (−0.4 vs. −0.2, p = 0.17, 
ANCOVA).
Self-reported adverse effects included dry mouth 
(15/95, 15.8%) and constipation (6/95, 6.3%). No 
patient complained of cognitive impairment. Most of 
the adverse events were mild and tolerable, except 
in one patient who discontinued treatment due to 
severely dry mouth.
3.1. Subgroup analysis
3.1.1. NPi
As shown in Fig. 1, no statistically significant differ-
ences were noted in the mean reductions in number 
of nocturia episodes between patients with NPi > 0.35 
and those with NPi > 0.35 (−0.4 vs. −0.3, p = 0.34, 
ANCOVA). The mean number of nocturia episodes in 
patients with NPi > 0.35 (n = 21) reduced from 2.6 ± 1.3 
to 2.3 ± 1.1 (p = 0.30) after treatment. The mean number 
of nocturia episodes in patients with NPi ≤ 0.35 (n = 38) 
reduced from 2.7 ± 1.3 to 2.3 ± 1.1 (p < 0.01) after 
treatment.
3.1.2. Ni
As shown in Fig. 2, a significantly greater degree of 
reduction in number of nocturia episodes was noted in 
patients with Ni ≤ 1.5 compared to those with Ni > 1.5 
(−0.9 vs. −0.2, p = 0.02, ANCOVA). The mean number 
of nocturia episodes in patients with Ni ≤ 1.5 (n = 18) 
reduced from 3.2 ± 1.4 to 2.3 ± 0.9 (p < 0.01). The mean 
number of nocturia episodes in patients with Ni > 1.5 
(n = 41) reduced from 2.4 ± 1.2 to 2.2 ± 1.1 (p = 0.22).
3.1.3. NBCi
As shown in Fig. 3, a significantly greater degree of 
reduction in number of nocturia episodes was found 
in patients with NBCi > 2 compared to those with 
Table 1 — Patient demographics and comparisons of 
nocturia episodes, peak flow rate (Qmax), and post-void 
residual urine (PVR) between baseline and end point*
Patient characteristics
Case number 59
Age, yr (range) 47.9 ± 16.0 (19–82)
Male/Female 11/48
Nocturnal urine volume, mL 527.2 ± 323.9
Total daily urine volume, mL 1721.5 ± 587.3
Maximal voided volume, mL 319.2 ± 120.6
 Baseline End point p
Nocturia episodes 2.7 ± 1.3 2.3 ± 1.1 < 0.01
Qmax, mL/sec 17.6 ± 1.4 17.5 ± 1.2 0.96
Voided volume, mL 211.0 ± 19.1 243.3 ± 20.4 0.10
PVR, mL 33.5 ± 4.5 37.6 ± 5.8 0.36
*Data presented as n or mean ± standard deviation.
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Fig. 1 — Patients with NPi ≤ 0.35 did not have significantly 
fewer episodes of nocturia at end point compared with 
those with NPi > 0.35 (p = 0.34).
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Fig. 2 — Patients with Ni ≤ 1.5 had significantly fewer epi-
sodes of nocturia at end point compared with those with 
Ni > 1.5 (p = 0.03).
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Fig. 3 — Patients with NBCi > 2 had significantly fewer epi-
sodes of nocturia at end point compared with those with 
NBCi ≤ 2 (p = 0.01).
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NBCi ≤ 2 (−1.1 vs. −0.2, p = 0.01, ANCOVA). The mean 
number of nocturia episodes in patients with NBCi > 2 
(n = 16) reduced from 3.6 ± 1.5 to 2.5 ± 1.1 (p < 0.01). 
The mean number of nocturia episodes in patients 
with NBCi ≤ 2 (n = 43) reduced from 2.4 ± 1.1 to 2.2 ± 1.1 
(p = 0.20).
4. Discussion
Ni and NBCi, which take into account MVV and noc-
turnal bladder capacity, may be the main factors pre-
dicting better response to antimuscarinic agents in 
OAB patients with nocturia. In this study, oxybutynin 
significantly reduced number of nocturia episodes, 
particularly in patients with Ni ≤ 1.5 or NBCi > 2 
(p < 0.05). Relatively small nocturnal urine volume 
alone (NPi ≤ 0.35) was not sensitive enough to predict 
better treatment response to oxybutynin (p = 0.34).
It has been well established that patients with 
higher NPi are considered to have excessive nocturnal 
urine production [4] and have favorable responses to 
desmopressin [6]. However, NPi ≤ 0.35 is not a good 
predictor of treatment response to oxybutynin. NPi 
just indicates nocturnal urine production and does 
not take bladder capacity into consideration. In fact, 
when nocturnal urine volume is greater than bladder 
capacity, nocturia occurs [7]. Patients may wake up 
in the night to void with either large or small volume, 
as long as their bladders are full.
In addition, similar to the results of Weiss et al [8], 
we found that nocturnal polyuria played a minor role 
in the pathophysiology of nocturia in OAB patients 
younger than 50 years. The mean age of our patients 
was 47.9 years, which was lower than the mean age of 
56–58 years in the other series. The proportion of 
studied patients with nocturnal polyuria was 35.6%, 
which was less than that of previous studies (range, 
43–62%) [3,8].
Patients without nocturnal urine overproduction 
in excess of his/her maximal bladder capacity bene-
fited more from oxybutynin treatment, i.e., patients 
with Ni ≤ 1.5 had a greater decrease in the episodes of 
nocturia than those with Ni > 1.5. (0.9 vs. 0.2, p = 0.03). 
Higher Ni values imply nocturnal urine overproduction 
relative to functional bladder capacity [5]. Rembratt 
et al [7] evaluated differences in FVC among elderly 
people with and without nocturia, and proposed that 
Ni was a statistically significant predictor of nocturia in 
the elderly. Weiss et al [8] noted that Ni of 1.5 was a 
threshold, in which higher values meant that nocturia 
may be attributed to nocturnal urine overproduction 
in excess of maximal bladder capacity.
Patients with diminished nocturnal bladder capacity 
can benefit from oxybutynin treatment. Higher NBCi 
values imply that the underlying pathophysiology of 
the nocturia is due to decreased nocturnal bladder 
capacity. Weiss et al [8] proposed NBCi > 2 as a highly 
significant predictor of diminished nocturnal bladder 
capacity and a major cause of nocturia. We concur 
that a greater reduction in number of nocturia epi-
sodes was noted in patients with NBCi > 2 than in 
those with NBCi ≤ 2 (1.1 vs. 0.2, p = 0.01).
Through antimuscarinic, spasmolytic, and local an-
esthetic effects, oxybutynin has been widely adopted 
to treat OAB and nocturia [9]. However, the effects of 
antimuscarinics on nocturia in OAB patients remain 
controversial. Kreder et al [10] also reported good 
responses to tolterodine in OAB patients with nocturia. 
Johnson et al [11] mentioned that oxybutynin reduced 
nocturia by a median of 0.30 episodes per night and 
was significantly more effective than the median re-
duction (0.00 episode) in the placebo-controlled group 
(p = 0.07). Our results demonstrated that oxybutynin 
also significantly reduced the mean number of noc-
turia episodes from 2.7 ± 1.3 to 2.3 ± 1.1 (p < 0.01). It is 
rapidly absorbed from the gastrointestinal tract after 
oral intake and has a half-life of 2–3 hours. Its metabo-
lite, N-desethyloxybutynin, also possesses the anti-
cholinergic effects of its parent compound. Thus, the 
effects of oxybutynin can last for 4–6 hours [12]. Since 
patients took the second dose of oxybutynin before 
they slept, oxybutynin had effects on their bladders 
during their sleep and therefore reduced nocturia 
episodes. In addition, since oxybutynin is cheaper 
than tolterodine, it is more cost-effective for treating 
nocturia.
In the present study, we adopted a 2-day FVC in-
stead of a 7-day FVC. Some authors consider that 
the wide variability in FVC makes these urinary indi-
ces unconvincing and that a 7-day FVC is usually 
needed to achieve more accurate results [13]. How-
ever, the duration of the voiding diary may be related 
to patient compliance and be burdensome [14]. The 
reported drop-out rate of the 2-day or 3-day FVC is 
high and recordings have been complete in only 60% 
of patients [15]. We adopted the 2-day diary to improve 
patient compliance, resulting in 78.9% (75/95) com-
pleted FVC records. Since both men and women work 
in our current society, a 7-day diary may not be prac-
tical. In addition, the parameters generated from the 
2-day FVC provided good information in predicting 
treatment responses to oxybutynin. Dmochowski et al 
[16] confirmed that 3-day diaries were as equally effec-
tive as 7-day diaries and may have better accuracy due 
to increased patient compliance.
There were several limitations in the study. First, 
due to the limited number of cases enrolled, patients 
without nocturnal polyuria did not demonstrate sta-
tistically significant responses to oxybutynin compared 
with those with nocturnal polyuria. Second, nocturia 
was not an initial inclusion criterion of the study. 
Nocturia in patients with OAB may not be represent-
ative of nocturia in the general population. Third, the 
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study duration was only 1 week due to the rapid onset 
of responses to oxybutynin therapy. Finally, we admit 
that there was little improvement in reductions in the 
number of nocturia episodes (−0.4) among these 
patients. With such a small degree of reduction in the 
number of nocturia episodes (despite statistical sig-
nificance), patients will not see any improvement to 
their quality of life. Of course, the effects may be partly 
due to the placebo effect, and placebo effect on lower 
urinary tract symptoms will tend to wear off after long-
term therapy. Future placebo-controlled study with a 
longer duration of observation is warranted to con-
firm the therapeutic effects of oxybutynin. Therefore, 
the main purpose of the present study was to find 
out which factors could predict better responses to 
anticholinergic agents. In our study, we used Ni and 
NBCi as predictors and showed that patients with re-
duced nocturnal bladder capacity may benefit more 
from treatment with anticholinergic agents.
5. Conclusion
Ni and NBCi are predictive factors for the effects of 
antimuscarinic agents in the treatment of nocturia in 
OAB patients. Nocturnal urine volume alone is not a 
reliable predicting factor.
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